The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer

  • Elske C. Gootjes
  • , Lotte Bakkerus
  • , Albert J. ten Tije
  • , Petronella O. Witteveen
  • , Tineke E. Buffart
  • , John A. Bridgewater
  • , John N. Primrose
  • , Cornelis Verhoef
  • , Henk M.W. Verheul*
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Local treatment of metastases by surgical resection or other ablative therapies is technically feasible in an increasing number of patients with multi-organ metastatic cancer. This results in a growing debate on whether patients with extensive disease, that is traditionally deemed unresectable, may benefit from local treatment of metastases when added to standard palliative systemic therapy. For selected patients with oligometastatic colorectal cancer, local treatment of metastases has become the standard of care based on retrospective reports showing long-term survival rates. In addition to systemic therapy, preliminary evidence suggests that patients with extensive metastatic colorectal cancer may also benefit from local treatment. Here, we present the future perspectives based on the available literature on local treatment approaches in colorectal cancer.

Original languageEnglish
Pages (from-to)160-164
Number of pages5
JournalEuropean Journal of Cancer
Volume103
Early online date19 Sept 2018
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • Colorectal carcinoma
  • Extrahepatic disease
  • Tumour debulking

Fingerprint

Dive into the research topics of 'The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this